Dergiler / Clinical and Experimental Health Sciences / 2018 / Cilt: 8 - Sayı: 3

Protective Effects of Montelukast Against Stress-Induced Degeneration of the Urinary Bladder

Sayfa
211–216
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Moreover,significant decrease in MDA and increase in GSH levels were observed in this group.Conclusion: Montelukast appears to exert a protective activity in WAS inducedurinary bladder injury by inhibiting inflammatory and oxidative activity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of the study was to investigate the role of montelukast (ML), acysteinyl leukotriene-1 receptor antagonist, on the water avoidance stress (WAS) –induced degeneration of the rat urinary bladder mucosa.Methods: In WAS group, rats were exposed to WAS two hours daily for five days.In WAS+ML group, rats were administered ML (10 mg/kg; i.p.;) following every WASexposure for 5 days.
📊
Temel Bulgular & Veri:Tissuemalondialdehyde (MDA) and gluthatione (GSH) levels were also analysed.Results: Irregular GAG layer and uroplakin distribution, penetration of RR inthe intercellular spaces and dilated tight junctions in urothelial layer, increase ininflammatory cell infiltration, in number of both granulated and activated mast cells,and were observed in the WAS group.
💡
Sonuç & Katkı:Moreover,significant decrease in MDA and increase in GSH levels were observed in this group.Conclusion: Montelukast appears to exert a protective activity in WAS inducedurinary bladder injury by inhibiting inflammatory and oxidative activity.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Water avoidance stress · montelukast · urinary bladder

Abstract

Objective: The aim of the study was to investigate the role of montelukast (ML), acysteinyl leukotriene-1 receptor antagonist, on the water avoidance stress (WAS) –induced degeneration of the rat urinary bladder mucosa.Methods: In WAS group, rats were exposed to WAS two hours daily for five days.In WAS+ML group, rats were administered ML (10 mg/kg; i.p.;) following every WASexposure for 5 days. In control group, rats were injected vehicle solution only. Theurinary bladder was evaluated for general morphology at light microscope. Mastcell activation and uroplakin distribution were assassed with immunohistochemistry.Glycosaminoglycan (GAG) distribution and urothelial permeability were observedusing ruthenium red (RR) staining techniques in transmission electron microscopeand luminal urothelial cells were observed with scanning electron microscope. Tissuemalondialdehyde (MDA) and gluthatione (GSH) levels were also analysed.Results: Irregular GAG layer and uroplakin distribution, penetration of RR inthe intercellular spaces and dilated tight junctions in urothelial layer, increase ininflammatory cell infiltration, in number of both granulated and activated mast cells,and were observed in the WAS group. The MDA level was increased, and GSH levelwas decreased significantly in urinary bladder in the WAS group in comparison withthe control group. Quite regular GAG layer, uroplakin distribution and tight junctionsin most regions, decrease in inflammatory cell infiltration and both of activated andgranulated mast cells in the mucosa, were observed in WAS+ML group. Moreover,significant decrease in MDA and increase in GSH levels were observed in this group.Conclusion: Montelukast appears to exert a protective activity in WAS inducedurinary bladder injury by inhibiting inflammatory and oxidative activity.

🔖

Bu Makaleye Atıf Yap

Çetinel, Ş., Şener, G., Ercan, F., Dülger, E. Ç., Çanıllıoğlu, Y. E. (2022). Protective Effects of Montelukast Against Stress-Induced Degeneration of the Urinary Bladder. Clinical and Experimental Health Sciences, Cilt: 8 - Sayı: 3, 211–216. https://ajindex.com/articles/474398

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008; 53(1):60-7.